Theresa Heggie insider trades: Biocryst Pharmaceuticals (BCRX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Theresa reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 20, 2026 | BCRX | ↓ Sell | 49,933 | $10.11 | $505K | Direct | Mar 24, 2026 (4d) |
| Aug 13, 2025 | BCRX | ↓ Sell | 70,000 | $8.51 | $596K | Direct | Aug 15, 2025 (2d) |
| Jun 14, 2024 | BCRX | ↓ Sell | 6,698 | $6.11 | $41K | Direct | Jun 14, 2024 (0d) |
| Nov 18, 2019 | BCRX | ↑ Buy | 5,000 | $1.45 | $7K | Direct | Nov 18, 2019 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other BCRX insiders
Open-market trades in the last 12 months
About Theresa Heggie's insider trades
Theresa Heggie is a director at Biocryst Pharmaceuticals (BCRX). Since Nov 18, 2019, Theresa has reported 1 open-market purchase worth $7K and 3 sales worth $1.1M on SEC Form 4. In the last 12 months: 1 sale ($505K).
Their filings also include grants and awards (29 filings), option exercises (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BCRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.